Table 1: Notable Influenza Pandemics
Table 2: Influenza Symptoms
Table 3: Seasonal Influenza Immunization Recommendation Agencies by Country, 2016
Table 4: Immunization Recommendations and Most Frequently Administered Seasonal Influenza Vaccines, 2016
Table 5: Country Profile –Japan
Table 6: Leading Seasonal Influenza Vaccines, 2016
Table 7: Product Profile – Fluzone Quadrivalent
Table 8: Immunogenicity Profile of Fluzone Quadrivalent
Table 9: Local and Systemic AEs of Fluzone Quadrivalent
Table 10: Fluzone Quadrivalent SWOT Analysis, 2016
Table 11: Global Sales Forecast ($m) for Fluzone Quadrivalent, 2015–2025
Table 12: Product Profile – Fluzone High-Dose
Table 13: Immunogenicity of Fluzone High-Dose Compared with Fluzone
Table 14: Local and Systemic AEs of Fluzone High-Dose
Table 15: Fluzone High-Dose SWOT Analysis, 2016
Table 16: Global Sales Forecast ($m) for Fluzone High-Dose, 2015–2025
Table 17: Product Profile – Fluzone Intradermal
Table 18: Comparison of Fluzone Intradermal Quadrivalent Versus Fluzone Intradermal Trivalent
Table 19: Local andsystemic AEs of Fluzone Intradermal Quadrivalent
Table 20: Fluzone Intradermal Quadrivalent SWOT Analysis, 2016
Table 21: Global Sales Forecast ($m) for Fluzone/Intanza Intradermal, 2015–2025
Table 22: Product Profile – Vaxigrip
Table 23: Cumulative Incidence of Influenza Infection in Children
Table 24: Local and Systemic AEs of Vaxigrip
Table 25: Vaxigrip SWOT Analysis, 2016
Table 26: Global Sales Forecast ($m) for Vaxigrip, 2015–2025
Table 27: Product Profile – Fluarix Tetra
Table 28: Immunogenicity Profile of Fluarix Tetra
Table 29: Local and Systemic AEs of Fluarix Tetra
Table 30: Fluarix Tetra SWOT Analysis, 2016
Table 31: Global Sales Forecast ($m) for Fluarix Tetra, 2015–2025
Table 32: Product Profile – Fluvirin
Table 33: Immunogenicity of Fluvirin in Adults
Table 34: Local and Systemic AEs of Fluvirin
Table 35: Fluvirin SWOT Analysis, 2016
Table 36: Global Sales Forecast ($m) for Fluvirin, 2015–2025
Table 37: Product Profile – Afluria
Table 38: Immunogenicity of Afluria in Adults
Table 39: Local and Systemic AEs of Afluria
Table 40: Afluria SWOT Analysis, 2016
Table 41: Global Sales Forecast ($m) for Afluria, 2015–2025
Table 42: Product Profile – Agrippal
Table 43: Immunogenicity of Agrippal
Table 44: Local and Systemic AEs of Agrippal
Table 45: Agrippal SWOT Analysis, 2016
Table 46: Global Sales Forecast ($m) for Agrippal, 2015–2025
Table 47: Product Profile – Fluad
Table 48: Immunogenicity Comparison of Fluad Versus Agriflu
Table 49: Local and Systemic AEs of Fluad
Table 50: Fluad SWOT Analysis, 2016
Table 51: Global Sales Forecast ($m) for Fluad, 2015–2025
Table 52: Product Profile – FluMist Quadrivalent
Table 53: Noninferiority of FluMist Quadrivalent Compared with FluMist Trivalent
Table 54: AEs of FluMist Quadrivalent
Table 55: FluMist Quadrivalent SWOT Analysis, 2016
Table 56: Global Sales Forecast ($m) for FluMist Quadrivalent, 2015–2025
Table 57: Product Profile – Flublok
Table 58: Immunogenicity of Flublok compared with Fluzone and Fluzone High-Dose
Table 59: Local and Systemic AEs of Flublok
Table 60: Flublok SWOT Analysis, 2016
Table 61: Global Sales Forecast ($m) for Flublok, 2015–2025
Table 62: Product Profile – Flucelvax
Table 63: Immunogenicity of Flucelvax
Table 64: Local and Systemic AEs of Flucelvax
Table 65:Flucelvax SWOT Analysis, 2016
Table 66: Global Sales Forecast ($m) for Flucelvax, 2015–2025
Table 67: Summary of Other Marketed Seasonal Influenza Vaccines, 2016
Table 68: Unmet Need and Opportunity in Seasonal Influenza Vaccines, 2016
Table 69: Seasonal Influenza Vaccines – Late-Stage Pipeline, 2016
Table 70: Quadrivalent Versions of Marketed Vaccines
Table 71: Product Profile – Seasonal Influenza VLP Vaccine
Table 72: Seasonal Influenza VLP Vaccine SWOT Analysis, 2016
Table 73: Global Sales Forecast ($m) for Seasonal Influenza VLP Vaccine, 2015–2025
Table 74: Product Profile – VN-100
Table 75: Comparison of Immunogenicity Profile of VN-100 and Subcutaneous Standard Vaccine
Table 76: Frequency of Local and Systemic AEs of VN-100 Compared with a Comparator Subcutaneous Vaccine
Table 77: VN-100 SWOT Analysis, 2016
Table 78: Global Sales Forecast ($m) for VN-100, 2015–2025
Table 79: Product Profile – Quadrivalent Seasonal Influenza VLP Vaccine
Table 80: Quadrivalent Seasonal Influenza VLP Vaccine SWOT Analysis, 2016
Table 81: Global Sales Forecast ($m) for Quadrivalent Seasonal Influenza VLP Vaccine, 2015–2025
Table 82: Promising Vaccines in Early-Stage Development, 2016
Table 83: Summary of Seasonal Influenza Vaccines in Development Outside the 7MM, 2016
Table 84: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Japan, 2015–2025
Table 85: Key Events Impacting Sales for Seasonal Influenza in Japan 2015?2025
Table 86: Japan Seasonal Influenza Vaccines Market – Drivers and Barriers, 2015?2025
Table 87: Key Launch Dates
Table 88: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
